Abiraterone + Prednisone + LHRH Effective as Second-Line Treatment for Salivary Gland Cancer?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
On October 1, 2021, Laura D. Locati and colleagues from Fondazione IRCCS Istituto Nazionale dei Tumori published the effectiveness and safety results of the Phase II clinical trial using the CYP17 inhibitor Abiraterone + Prednisone + LHRH as a second-line treatment for patients with androgen receptor-positive salivary gland cancer in the medical journal "Journal of Clinical Oncology."
In this Phase II clinical trial, patients with androgen receptor-positive salivary gland cancer (N=24) received Abiraterone (1g) once daily + Prednisone (10mg) + LHRH as second-line treatment. The primary endpoint was the objective response rate (ORR), and secondary endpoints included the disease control rate (DCR), safety, progression-free survival (PFS), and overall survival (OS).
The median age of patients in this trial was 65.8 years. The primary endpoint, objective response rate, was 21%, with 5 patients achieving a partial response. The secondary endpoints included a disease control rate of 62.5%, a duration of response (DOR) of 5.82 months, a median progression-free survival of 3.65 months, and a median overall survival of 22.47 months.
Regarding safety, the incidence of side effects was 92% (N=22). The incidence of Grade 3 side effects was 25% (N=6), which included fatigue (2 patients), hot flashes (1 patient), and supraventricular arrhythmia (1 patient).
Based on the results of the Phase II clinical trial, Laura D. Locati and others stated that the use of the CYP17 inhibitor Abiraterone + Prednisone + LHRH as second-line treatment in patients with androgen receptor-positive salivary gland cancer was well-tolerated with no significant safety concerns.
Source: https://ascopubs.org/doi/full/10.1200/JCO.21.00468
-
Clinical Trial Drugs
(Lung Cancer) Phase II Clinical Trial Results of Topotecan and Topotecan + Berzosertib Treatment. (Lung Cancer) Is Enhertu Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is the Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4